Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Effect of breviscapine against hepatic ischemia reperfusion injury.

Authors: Lin, Yan-Zhu  Lu, Zhi-Yuan  Liang, Xiao-Hui  Li, Kang  Peng, Bo  Gong, Jin 
Citation: Lin YZ, etal., J Surg Res. 2016 Jun 15;203(2):268-74. doi: 10.1016/j.jss.2016.02.013. Epub 2016 Feb 19.
Pubmed: (View Article at PubMed) PMID:27363631
DOI: Full-text: DOI:10.1016/j.jss.2016.02.013

BACKGROUND: Breviscapine is an active ingredient extracted from traditional Chinese medicine Erigeron breviscapus. The purpose of this study was to investigate the effect of breviscapine injection on hepatic ischemia and/or reperfusion injury.
METHODS: Forty rats were randomly divided into five groups (n = 8): Sham group, Ischemia reperfusion 1 (I/R1) + normal saline (NS) group, I/R1 + breviscapine (Bre), I/R2 + NS group, and I/R2 + Bre group. Group1 and group2 represent ischemia time for 10 min and 30 min, respectively. Breviscapine or normal saline was administered to rats (single dose of 10 mg/Kg, intravenously) 30 min before hepatic ischemia. Serum transaminases, histopathologic changes, malondialdehyde (MDA), and superoxide dismutase (SOD) in liver tissues were evaluated. The expression level of mitochondrial fusion 2 (Mfn2) was also investigated.
RESULTS: After 24-h reperfusion, based on the histopathologic analysis, compared with NS control group, the liver function was improved in breviscapine group. Liver enzymes aspartate and alanine aminotransferase levels were significantly lower in the I/R + Bre group, when compared with the I/R + NS group. Pretreatment with breviscapine reduced MDA level (P < 0.05) and increased SOD activity significantly in I/R + Bre compared with I/R + NS group. Western blot and RT-q polymerase chain reaction showed that Mfn2 was significantly downregulated in breviscapine preconditioning group as compared to normal saline control group.
CONCLUSIONS: Breviscapine preconditioning attenuates liver ischemia reperfusion injury via inhibiting liver oxidative stress reaction. The protective mechanism probably inhibits Mfn2 protein and mRNA expression.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 12910833
Created: 2017-06-26
Species: All species
Last Modified: 2017-06-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.